Trials / Completed
CompletedNCT00313170
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg
Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 144 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 45 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fulvestrant | intramuscular injection 250 mg \& 500 mg |
Timeline
- Start date
- 2006-05-30
- Primary completion
- 2008-06-13
- Completion
- 2019-03-13
- First posted
- 2006-04-12
- Last updated
- 2020-01-06
- Results posted
- 2011-08-29
Locations
34 sites across 8 countries: Belgium, Canada, Czechia, France, Hungary, Poland, Romania, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00313170. Inclusion in this directory is not an endorsement.